Matten Bei Interlaken

Researchers are studying the safety and effectiveness of the Dexter Robotic System for patients undergoing robotic-assisted right colectomy, a surgical procedure on the colon. The purpose is to confirm how well this robotic system performs during and shortly after surgery, focusing on both safety and clinical outcomes. Participants will receive a right colectomy using the Dexter robotic surgery system. This device assists surgeons during the operation. The study will monitor patients through the perioperative period and up to 30 days after surgery to assess the safety and performance of the robotic system. During the study, participants will be followed for 30 days after surgery, with assessments following the standard of care. Researchers will measure safety outcomes within this period and evaluate the effectiveness of the procedure during the operation itself. Patient follow-up is important to understand the early postoperative effects and overall clinical performance of the device.

Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that arise from the neuroendocrine system in the gastrointestinal tract and pancreas. This registry study aims to better understand these tumors by collecting detailed clinical information from patients diagnosed with GEP-NETs in Switzerland. Since limited knowledge exists about the biology and treatment of these tumors, the study focuses on gathering data to improve understanding and management strategies. Patients with a confirmed diagnosis of neuroendocrine tumors from any location who agree to participate will have their information entered prospectively into a secure, anonymized database. Data collection involves visits from study nurses to healthcare centers, where patient files are reviewed and information is recorded. There are no specific treatments assigned by this registry; instead, it tracks various treatment approaches used in Switzerland. Participants contribute data that includes tumor types, treatments received, and outcomes such as mortality and hospitalization rates. The study reviews and evaluates this information regularly to identify patterns and assess patient outcomes over time. The main outcome measured is tumor-related mortality every five years, helping to monitor long-term effects. This registry allows for improved knowledge sharing across hospitals and practitioners in Switzerland to enhance care for patients with neuroendocrine tumors.